NDAORALFOR SUSPENSION, TABLET
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TROVAN/ZITHROMAX COMPLIANCE PAK is a fixed-dose combination oral product containing azithromycin (a macrolide antibiotic) and trovafloxacin (a fluoroquinolone antibiotic) approved in 1998 for bacterial infections. This dual-agent compliance pack is designed to improve patient adherence by combining two complementary antibiotics in a single regimen. The combination leverages the broad-spectrum activity of both agents to target respiratory and other systemic infections.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating defensive commercial strategy and potential team downsizing or portfolio transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TROVAN/ZITHROMAX offers limited upside career opportunity due to LOE-approaching status and zero linked job openings. This assignment is suitable for professionals managing portfolio transitions, defending market share against generics, or optimizing pricing/access strategies in a declining revenue environment.
Brand ManagerField Sales Representative
Worked on TROVAN/ZITHROMAX COMPLIANCE PAK at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.